• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SNT
Click for more information
10.0% 5.5¢

SYNTARA LIMITED - Charts / Financials

Market Cap $41.29M  ! watchlist Created with Sketch. Add to my watchlist

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 14.39pm 29/11/2024 (20 minute delay) ?
Day
Open 5.2¢   Day High 5.6¢   Day Low 5.2¢
Daily Volume 9826333
Bids   Sellers
Number Price Volume   Number Price Volume
2 5.5¢ 204460   1 5.6¢ 100000

Directors & Senior Management

Mr. Gary Jonathan Phillips Chief Executive Officer, Managing Director, Executive Director
Mr. David Morris Mcgarvey Chief Financial Officer, Company Secretary
Dr. Jana Baskar Chief Medical Officer
Mr. Wolfgang G. Jarolimek Head - Drug Discovery
Ms. Kristen Morgan Alliance Management and Head - Medical and Regulatory Affairs
Dr. Kathleen Mary Metters Non-Executive Chairman of the Board
Mr. Waradana Malitha Hashan De Silva Non-Executive Director
Dr. Simon P. Green Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
5.5¢ 		Change
0.005(10.0%) 		Mkt cap ! $41.29M
Open High Low Value Volume
5.2¢ 5.6¢ 5.2¢ $527.6K 9.826M

Buyers (Bids)

No. Vol. Price($)
2 204460 5.5¢
 

Sellers (Offers)

Price($) Vol. No.
5.6¢ 100000 1
View Market Depth
Last trade - 14.16pm 29/11/2024 (20 minute delay) ?
Last
5.7¢ 		  Change
0.005 ( 15.2 %)
Open High Low Volume
5.3¢ 5.7¢ 5.2¢ 1368404
Last updated 14.39pm 29/11/2024 ?

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Parkes Au-Cu project to 'transform' Adavale Resources with key targets Adavale Resources Ltd has entered into an all-scrip acquisition of the Parkes gold and copper project in New South Wales
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.